why choose us

300×250 Ad Slot

Drug FDA Status

Showing 10 of 196 result(s) (Page 1 of 20)
Drug Name: Hibsago

Active Ingredient: bepirovirsen

Approval Date: 2026-10-20

Description: To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy

Drug Name: Hovilpri

Active Ingredient: pritelivir

Approval Date: 2026-10-09

Description: To treat adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus infection and have not responded to other therapies

Drug Name: Emcitate

Active Ingredient: tiratricol

Approval Date: 2026-09-28

Description: To treat peripheral thyrotoxicosis in patients with MCT8 deficiency

Drug Name: Juvmo

Active Ingredient: tavapadon

Approval Date: 2026-09-25

Description: To treat Parkinson’s disease in adults

Drug Name: Atebrioz

Active Ingredient: zilurgisertib

Approval Date: 2026-09-25

Description: To reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva

Drug Name: Onswik

Active Ingredient: insulin efsitora alfa-gobe

Approval Date: 2026-09-23

Description: To improve glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise

Drug Name: Lyrfigtu

Active Ingredient: lirafugratinib

Approval Date: 2026-09-23

Description: To adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement

Drug Name: Isembyld

Active Ingredient: apitegromab-mstn

Approval Date: 2026-09-11

Description: To treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment

Drug Name: Pixclara

Active Ingredient: floretyrosine F 18

Approval Date: 2026-09-11

Description: To use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change in conjunction with other diagnostic evaluations

Drug Name: Etcamah

Active Ingredient: camizestrant

Approval Date: 2026-09-04

Description: To treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy

300×250 Ad Slot